Stay updated with breaking news from Future Royalties. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for...
- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival... | May 3, 2023
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous
Investegate announcements from Minerva Neurosciences, Inc, Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022WALTHAM, Mass., Aug. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused